Larimar Therapeutics, Inc. - Common Stock, par value $0.01 per share (LRMR) Institutional Ownership

CUSIP: 517125100

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.01 per share
Symbol
LRMR on Nasdaq
Shares outstanding
103,654,385
Price per share
$5.52
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
72,424,903
Total reported value
$275,932,718
% of total 13F portfolios
0%
Share change
-12,638,977
Value change
-$38,772,040
Number of holders
135
Price from insider filings
$5.52
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 517125100?
CUSIP 517125100 identifies LRMR - Larimar Therapeutics, Inc. - Common Stock, par value $0.01 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Larimar Therapeutics, Inc. - Common Stock, par value $0.01 per share (LRMR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Flynn James E 34% -3.9% $123,052,785 +$17,250,000 35,667,474 +16% Deerfield Management Company, L.P. 27 Feb 2026
Blue Owl Capital Holdings LP 10% $28,187,328 8,464,663 Blue Owl Capital Holdings LP 31 Dec 2025
MILLENNIUM MANAGEMENT LLC 5.8% +3.3% $16,043,858 +$4,532,710 4,966,831 +39% Millennium Management LLC 30 Sep 2025
Opaleye Management Inc. 4.8% -23% $15,412,500 +$590,966 4,110,000 +4% Opaleye Management, Inc. 29 Aug 2025
BlackRock, Inc. 4.8% -6% $7,175,619 -$433,939 3,079,665 -5.7% BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 4.1% $6,058,491 2,600,211 THE GOLDMAN SACHS GROUP, INC. 31 Mar 2025

As of 31 Dec 2025, 135 institutional investors reported holding 72,424,903 shares of Larimar Therapeutics, Inc. - Common Stock, par value $0.01 per share (LRMR). This represents 70% of the company’s total 103,654,385 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Larimar Therapeutics, Inc. - Common Stock, par value $0.01 per share (LRMR) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
DEERFIELD MANAGEMENT COMPANY, L.P. 30% 30,606,974 0% 1.5% $116,612,571
Blue Owl Capital Holdings LP 6.6% 6,823,690 +17% 8% $25,998,259
MILLENNIUM MANAGEMENT LLC 5% 5,206,364 +6.3% 0.01% $19,836,247
BlackRock, Inc. 3.6% 3,681,603 +10% 0% $14,026,908
RTW INVESTMENTS, LP 3% 3,125,000 0% 0.12% $11,906,250
VANGUARD GROUP INC 2.9% 3,046,216 -1.3% 0% $11,606,083
AIGH Capital Management LLC 1.9% 2,000,000 +100% 2.3% $7,620,000
Point72 Asset Management, L.P. 1.4% 1,461,028 +19% 0.01% $5,566,517
CITADEL ADVISORS LLC 1.3% 1,366,750 -7.5% 0% $5,207,317
GOLDMAN SACHS GROUP INC 1.3% 1,347,215 -14% 0% $5,132,889
GEODE CAPITAL MANAGEMENT, LLC 1.1% 1,093,323 +6.9% 0% $4,166,238
DAFNA Capital Management LLC 0.91% 939,164 -8.6% 0.83% $3,578,215
Alyeska Investment Group, L.P. 0.9% 927,821 -51% 0.01% $3,534,998
STATE STREET CORP 0.88% 911,925 +2.2% 0% $3,474,434
Woodline Partners LP 0.77% 800,850 -51% 0.01% $3,051,239
JANE STREET GROUP, LLC 0.66% 678,942 +61% 0% $2,586,769
Verition Fund Management LLC 0.55% 567,683 0% 0.01% $2,162,872
Driehaus Capital Management LLC 0.52% 535,464 0% 0.01% $2,040,118
AQR CAPITAL MANAGEMENT LLC 0.48% 502,251 -11% 0% $1,913,576
D. E. Shaw & Co., Inc. 0.42% 437,399 0% $1,666,490
Caption Management, LLC 0.4% 415,294 -68% 0.07% $1,582,270
FEDERATED HERMES, INC. 0.35% 358,907 +14886% 0% $1,367,435
NORTHERN TRUST CORP 0.34% 356,775 -5.7% 0% $1,359,312
ExodusPoint Capital Management, LP 0.33% 344,246 +111% 0.01% $1,311,577
DIMENSIONAL FUND ADVISORS LP 0.32% 327,494 +482% 0% $1,247,752

Institutional Holders of Larimar Therapeutics, Inc. - Common Stock, par value $0.01 per share (LRMR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 72,424,903 $275,932,718 -$38,772,040 $3.81 135
2025 Q3 85,496,565 $274,794,131 +$75,244,593 $3.23 135
2025 Q2 62,321,311 $180,120,860 +$7,437,034 $2.89 116
2025 Q1 60,827,153 $131,864,050 -$12,271,759 $2.15 101
2024 Q4 63,434,614 $245,492,888 -$5,894,960 $3.87 115
2024 Q3 64,329,070 $421,287,622 -$5,929,383 $6.55 122
2024 Q2 65,308,461 $473,379,696 +$12,179,883 $7.25 105
2024 Q1 63,594,662 $482,627,362 +$182,781,336 $7.59 102
2023 Q4 39,456,509 $179,551,948 +$15,220,703 $4.55 69
2023 Q3 38,745,394 $153,032,401 -$3,458,223 $3.95 63
2023 Q2 39,027,692 $120,194,716 -$3,770,373 $3.13 65
2023 Q1 38,462,442 $174,244,129 +$1,086,191 $4.53 68
2022 Q4 38,766,976 $160,093,910 +$976,279 $4.13 47
2022 Q3 38,715,175 $123,902,000 +$77,822,908 $3.20 52
2022 Q2 14,391,311 $28,222,000 -$2,241,518 $1.96 34
2022 Q1 15,257,103 $61,778,000 -$2,584,495 $4.05 40
2021 Q4 14,567,301 $157,170,000 -$456,088 $10.79 47
2021 Q3 14,519,322 $167,488,004 +$199,976 $11.53 50
2021 Q2 14,543,964 $142,828,000 -$4,477,645 $9.82 42
2021 Q1 14,110,404 $206,147,000 -$8,290,625 $14.61 53
2020 Q4 14,252,270 $305,135,000 +$10,378,818 $21.41 42
2020 Q3 13,625,016 $206,745,000 +$10,359,632 $15.17 37
2020 Q2 12,953,044 $166,142,000 +$166,142,000 $12.85 34